WallStreetZenWallStreetZen

NASDAQ: HALO
Halozyme Therapeutics Inc Earnings & Revenue

HALO past earnings growth

How has HALO's earnings growth performed historically?
Company
84.21%
Industry
24.33%
Market
130.69%
HALO's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
HALO's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
HALO's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

HALO past revenue growth

How has HALO's revenue growth performed historically?
Company
22.41%
Industry
84.7%
Market
19.99%
HALO's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
HALO's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
HALO's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

HALO earnings and revenue history

Current Revenue
$863.0M
Current Earnings
$318.8M
Current Profit Margin
36.9%

HALO Return on Equity

Current Company
192.7%
Current Industry
16.9%
Current Market
28.2%
HALO's Return on Equity (192.7%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when HALO announces earnings.

HALO Return on Assets

Current Company
17.5%
Current Industry
3.2%
HALO is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

HALO Return on Capital Employed

Current Company
24.03%
Current Industry
-42.5%
HALO has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

HALO vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
HALO$862.99M$495.45M$318.80M+37.13%+101.37%
EXEL$1.85B$312.76M$205.05M+16.63%-21.67%
RVMD$4.57M-$477.95M-$484.27M-44.59%N/A
IONS$776.62M-$254.76M-$384.77M+0.63%N/A
BPMC$282.21M-$246.69M-$288.29M+44.82%N/A

HALO earnings dates

Next earnings date
Aug 6, 2024

Halozyme Therapeutics Earnings & Revenue FAQ

What were HALO's earnings last quarter?

On Invalid Date, Halozyme Therapeutics (NASDAQ: HALO) reported Q1 2024 earnings per share (EPS) of $0.61, up 110.34% year over year. Total Halozyme Therapeutics earnings for the quarter were $76.82 million. In the same quarter last year, Halozyme Therapeutics's earnings per share (EPS) was $0.29.

If you're new to stock investing, here's how to buy Halozyme Therapeutics stock.

What was HALO's earnings growth in the past year?

As of Q2 2024, Halozyme Therapeutics's earnings has grown 84.21% year over year. This is 59.88 percentage points higher than the US Biotechnology industry earnings growth rate of 24.33%. Halozyme Therapeutics's earnings in the past year totalled $318.80 million.

What is HALO's earnings date?

Halozyme Therapeutics's earnings date is Invalid Date. Add HALO to your watchlist to be reminded of HALO's next earnings announcement.

What was HALO's revenue last quarter?

On Invalid Date, Halozyme Therapeutics (NASDAQ: HALO) reported Q1 2024 revenue of $195.88 million up 20.81% year over year. In the same quarter last year, Halozyme Therapeutics's revenue was $162.14 million.

What was HALO's revenue growth in the past year?

As of Q2 2024, Halozyme Therapeutics's revenue has grown 22.41% year over year. This is 62.29 percentage points lower than the US Biotechnology industry revenue growth rate of 84.7%. Halozyme Therapeutics's revenue in the past year totalled $862.99 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.